The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
Stakheev, Dmitry
The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. [electronic resource] - Scientific reports 03 2019 - 4761 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2045-2322
10.1038/s41598-019-41182-5 doi
Aged
Antineoplastic Agents--pharmacology
CD4-Positive T-Lymphocytes--drug effects
Cell Line, Tumor
Heterocyclic Compounds, 3-Ring--pharmacology
Humans
Immunotherapy--methods
Male
Middle Aged
PC-3 Cells
Prostatic Neoplasms--drug therapy
T-Lymphocytes--cytology
Tankyrases--antagonists & inhibitors
Wnt Proteins--antagonists & inhibitors
Wnt Signaling Pathway--drug effects
beta Catenin--antagonists & inhibitors
The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. [electronic resource] - Scientific reports 03 2019 - 4761 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2045-2322
10.1038/s41598-019-41182-5 doi
Aged
Antineoplastic Agents--pharmacology
CD4-Positive T-Lymphocytes--drug effects
Cell Line, Tumor
Heterocyclic Compounds, 3-Ring--pharmacology
Humans
Immunotherapy--methods
Male
Middle Aged
PC-3 Cells
Prostatic Neoplasms--drug therapy
T-Lymphocytes--cytology
Tankyrases--antagonists & inhibitors
Wnt Proteins--antagonists & inhibitors
Wnt Signaling Pathway--drug effects
beta Catenin--antagonists & inhibitors